Cendakimab (RPC4046, CC-93538), a humanized IgG1k monoclonal antibody against IL-13, displayed potential efficacy in a multicenter trial (HEROES) of adult patients with active EoE. Here, IL13 is linked to eosinophilic esophagitis.